Damora Therapeutics, Inc. Common Stock (DMRA) is a publicly traded the market company. As of May 21, 2026, DMRA trades at $23.45 with a market cap of $1.53B and a P/E ratio of 0.00. DMRA moved +0.67% today. Year to date, DMRA is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $16.50 to $29.22. Analyst consensus is strong buy with an average price target of $44.40. Rallies surfaces DMRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Damora Secures $535M Runway, Targets DMR-001 IND Submission by Mid-2026: Damora Therapeutics held $535 million in cash as of February 28, 2026, following $285 million private and $316 million public financings, funding operations into Phase 3 for lead candidate DMR-001. The company expects IND or CTA submission for DMR-001 by mid-2026 and initial proof-of-concept data in mid-2027.
| Metric | Value |
|---|---|
| Price | $23.45 |
| Market Cap | $1.53B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $29.22 |
| 52-Week Low | $16.50 |
| Volume | 18 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
5 analysts cover DMRA: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $44.40.